Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab

READ-2 Investigators

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The study aims to identify the association between the baseline retinal vascular calibre and visual outcome of patients with diabetic macular oedema (DMO) treated with intravitreal ranibizumab. Methods: The 1-M field (as defined in the ETDRS study) of the digital colour fundus photographs of DMO patients who had been treated primarily with ranibizumab in a clinical trial was assessed. Of the 84 patients, 25 had gradable retinal photographs that could be subjected to analyses by the Interactive Vessel Analysis (IVAN) software at baseline. The average retinal vascular calibre of the six largest venules (CRVE) and the six largest arterioles (CRAE) in the peripapillary area (0.5 and 1 disc diameter from the optic disc margin) was measured. The relationship between CRVE and CRAE at baseline and the change in visual acuity at month 12 was assessed using the Mann-Whitney U test. Results Ten eyes from 10 patients who had shown an improvement of ≥2 lines of best corrected visual acuity (BCVA) at month 12 had a wider baseline CRVE (248.3±24.5 μm) compared with the 15 eyes from 15 patients who did not show the improvement of ≥2 lines (226.6±44.8 μm, P<0.05). The baseline CRAE did not differ significantly in these patients (156.1±22.7 vs 142±17.5 μm, P = 0.17). Conclusions: A wider baseline retinal venular calibre may be a predictor of better visual outcome in DMO eyes treated with ranibizumab. Further prospective studies with a larger sample size and a broader range of disease severity and visual acuity are needed to confirm this finding.

Original languageEnglish (US)
Pages (from-to)1315-1320
Number of pages6
JournalEye (Basingstoke)
Volume28
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Retinal Vessels
Macular Edema
Visual Acuity
Venules
Optic Disk
Arterioles
Nonparametric Statistics
Sample Size
Ranibizumab
Software
Color
Clinical Trials
Prospective Studies

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab. / READ-2 Investigators.

In: Eye (Basingstoke), Vol. 28, No. 11, 01.11.2014, p. 1315-1320.

Research output: Contribution to journalArticle

@article{2f8d8fe1214e468f801e6fb8ffb0692e,
title = "Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab",
abstract = "Purpose: The study aims to identify the association between the baseline retinal vascular calibre and visual outcome of patients with diabetic macular oedema (DMO) treated with intravitreal ranibizumab. Methods: The 1-M field (as defined in the ETDRS study) of the digital colour fundus photographs of DMO patients who had been treated primarily with ranibizumab in a clinical trial was assessed. Of the 84 patients, 25 had gradable retinal photographs that could be subjected to analyses by the Interactive Vessel Analysis (IVAN) software at baseline. The average retinal vascular calibre of the six largest venules (CRVE) and the six largest arterioles (CRAE) in the peripapillary area (0.5 and 1 disc diameter from the optic disc margin) was measured. The relationship between CRVE and CRAE at baseline and the change in visual acuity at month 12 was assessed using the Mann-Whitney U test. Results Ten eyes from 10 patients who had shown an improvement of ≥2 lines of best corrected visual acuity (BCVA) at month 12 had a wider baseline CRVE (248.3±24.5 μm) compared with the 15 eyes from 15 patients who did not show the improvement of ≥2 lines (226.6±44.8 μm, P<0.05). The baseline CRAE did not differ significantly in these patients (156.1±22.7 vs 142±17.5 μm, P = 0.17). Conclusions: A wider baseline retinal venular calibre may be a predictor of better visual outcome in DMO eyes treated with ranibizumab. Further prospective studies with a larger sample size and a broader range of disease severity and visual acuity are needed to confirm this finding.",
author = "{READ-2 Investigators} and A. Moradi and Sepah, {Y. J.} and Ibrahim, {M. A.} and R. Sophie and C. Moazez and Bittencourt, {M. G.} and Annam, {R. E.} and M. Hanout and H. Liu and D. Ferraz and Do, {D. V.} and Nguyen, {Q. D.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1038/eye.2014.186",
language = "English (US)",
volume = "28",
pages = "1315--1320",
journal = "Eye (London, England)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab

AU - READ-2 Investigators

AU - Moradi, A.

AU - Sepah, Y. J.

AU - Ibrahim, M. A.

AU - Sophie, R.

AU - Moazez, C.

AU - Bittencourt, M. G.

AU - Annam, R. E.

AU - Hanout, M.

AU - Liu, H.

AU - Ferraz, D.

AU - Do, D. V.

AU - Nguyen, Q. D.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose: The study aims to identify the association between the baseline retinal vascular calibre and visual outcome of patients with diabetic macular oedema (DMO) treated with intravitreal ranibizumab. Methods: The 1-M field (as defined in the ETDRS study) of the digital colour fundus photographs of DMO patients who had been treated primarily with ranibizumab in a clinical trial was assessed. Of the 84 patients, 25 had gradable retinal photographs that could be subjected to analyses by the Interactive Vessel Analysis (IVAN) software at baseline. The average retinal vascular calibre of the six largest venules (CRVE) and the six largest arterioles (CRAE) in the peripapillary area (0.5 and 1 disc diameter from the optic disc margin) was measured. The relationship between CRVE and CRAE at baseline and the change in visual acuity at month 12 was assessed using the Mann-Whitney U test. Results Ten eyes from 10 patients who had shown an improvement of ≥2 lines of best corrected visual acuity (BCVA) at month 12 had a wider baseline CRVE (248.3±24.5 μm) compared with the 15 eyes from 15 patients who did not show the improvement of ≥2 lines (226.6±44.8 μm, P<0.05). The baseline CRAE did not differ significantly in these patients (156.1±22.7 vs 142±17.5 μm, P = 0.17). Conclusions: A wider baseline retinal venular calibre may be a predictor of better visual outcome in DMO eyes treated with ranibizumab. Further prospective studies with a larger sample size and a broader range of disease severity and visual acuity are needed to confirm this finding.

AB - Purpose: The study aims to identify the association between the baseline retinal vascular calibre and visual outcome of patients with diabetic macular oedema (DMO) treated with intravitreal ranibizumab. Methods: The 1-M field (as defined in the ETDRS study) of the digital colour fundus photographs of DMO patients who had been treated primarily with ranibizumab in a clinical trial was assessed. Of the 84 patients, 25 had gradable retinal photographs that could be subjected to analyses by the Interactive Vessel Analysis (IVAN) software at baseline. The average retinal vascular calibre of the six largest venules (CRVE) and the six largest arterioles (CRAE) in the peripapillary area (0.5 and 1 disc diameter from the optic disc margin) was measured. The relationship between CRVE and CRAE at baseline and the change in visual acuity at month 12 was assessed using the Mann-Whitney U test. Results Ten eyes from 10 patients who had shown an improvement of ≥2 lines of best corrected visual acuity (BCVA) at month 12 had a wider baseline CRVE (248.3±24.5 μm) compared with the 15 eyes from 15 patients who did not show the improvement of ≥2 lines (226.6±44.8 μm, P<0.05). The baseline CRAE did not differ significantly in these patients (156.1±22.7 vs 142±17.5 μm, P = 0.17). Conclusions: A wider baseline retinal venular calibre may be a predictor of better visual outcome in DMO eyes treated with ranibizumab. Further prospective studies with a larger sample size and a broader range of disease severity and visual acuity are needed to confirm this finding.

UR - http://www.scopus.com/inward/record.url?scp=84987909279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987909279&partnerID=8YFLogxK

U2 - 10.1038/eye.2014.186

DO - 10.1038/eye.2014.186

M3 - Article

C2 - 25145456

AN - SCOPUS:84987909279

VL - 28

SP - 1315

EP - 1320

JO - Eye (London, England)

JF - Eye (London, England)

SN - 0950-222X

IS - 11

ER -